Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat(®) versus placebo and formoterol twice daily in patients with GOLD 2–4 COPD: results from two replicate 48-week studies

Two replicate, multicenter, randomized, double-blind, placebo-controlled, parallel-group, Phase III studies investigated the long-term efficacy and safety of once-daily olodaterol via Respimat(®) versus placebo and formoterol over 48 weeks in patients with moderate to very severe chronic obstructive...

Descripción completa

Detalles Bibliográficos
Autores principales: Koch, Andrea, Pizzichini, Emilio, Hamilton, Alan, Hart, Lorna, Korducki, Lawrence, De Salvo, Maria Cristina, Paggiaro, Pierluigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4094569/
https://www.ncbi.nlm.nih.gov/pubmed/25045258
http://dx.doi.org/10.2147/COPD.S62502

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4094569/
https://www.ncbi.nlm.nih.gov/pubmed/25045258
http://dx.doi.org/10.2147/COPD.S62502

Ejemplares similares